Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
about
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
P2860
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Acute myeloid leukemia after m ...... entity with a poor prognosis.
@ast
Acute myeloid leukemia after m ...... entity with a poor prognosis.
@en
type
label
Acute myeloid leukemia after m ...... entity with a poor prognosis.
@ast
Acute myeloid leukemia after m ...... entity with a poor prognosis.
@en
prefLabel
Acute myeloid leukemia after m ...... entity with a poor prognosis.
@ast
Acute myeloid leukemia after m ...... entity with a poor prognosis.
@en
P2093
P2860
P50
P1476
Acute myeloid leukemia after m ...... entity with a poor prognosis.
@en
P2093
Hady Ghanem
Mark Brandt
Sangbum Choi
Stephan Faderl
Xuelin Huang
P2860
P356
10.1016/J.CLML.2013.10.013
P407
P50
P577
2013-11-15T00:00:00Z